Kelley Lauren Coffman, MD, Responses to and Adverse Effects of Therapy With 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

Investigators observed a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera), according to study results presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, spoke about the results of the study and the toxicities she and her colleagues observed during the trial.

Transcription:

In the predominant results, we saw that there was good benefit in terms of disease stability from the treatment. About 63% of patients had a partial response to the therapy after completing 4 cycles, about 6% had stable disease, and unfortunately about a third of the patients, about 31%, did progress.

The other notable results were the toxicities. It was consistent with what was seen in the earlier trials, where the primary toxicity was bone marrow suppression and [aspartate aminotransferase; AST]/[alanine aminotransferase; ALT] elevation. But the severity in our patient population was not quite that high. We didn’t really see any grade 3 or grade 4 toxicities.

Reference:

Coffman KL, Bodei L, Le T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. J Clin Oncol. 2021;39(suppl 3). Abstract #: 368.